Litigation Details for Helsinn Healthcare S.A. v. Fresenius Kabi USA, LLC (D. Del. 2015)

« Back to Dashboard

Helsinn Healthcare S.A. v. Fresenius Kabi USA, LLC (D. Del. 2015)

Docket		Date Filed	2015-10-13
Court	District Court, D. Delaware	Date Terminated	2015-12-02
Cause	35:0145	Assigned To	Gregory Moneta Sleet
Jury Demand	None	Referred To
Parties	FRESENIUS KABI USA, LLC
Patents	7,947,724; 8,518,981; 8,598,218; 9,066,980; 9,125,905
Attorneys	Karen Jacobs
Firms	Morris, Nichols, Arsht & Tunnell
Link to Docket	External link to docket

Details for Helsinn Healthcare S.A. v. Fresenius Kabi USA, LLC (D. Del. 2015)

Date Filed	Document No.	Description	Snippet	Link To Document
2015-10-13				External link to document
2015-10-13	1		infringement of United States Patent No. 7,947,724 (“the ’724 patent”), United States Patent No. 8,518,981 (“the…, the ’724 patent, the ’981 patent, the ’218 patent, the ’980 patent, and the ’905 patent are listed …the ’981 patent”), United States Patent No. 8,598,218 (“the ’218 patent”), United States Patent No. 9,066,980…9,066,980 (“the ’980 patent”), and United States Patent No. 9,125,905 (“the ’905 patent”) (collectively, …, the “patents-in-suit”). This action arises under the patent laws of the United States, 35 U.S.C. §	External link to document
2015-10-13	4		the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 7,947,724; 8,518,981; 8,598,218…2015 2 December 2015 1:15-cv-00918 830 Patent None District Court, D. Delaware	External link to document

Helsinn Healthcare S.A. v. Fresenius Kabi USA, LLC: Litigation Summary and Patent Analysis

Last updated: September 24, 2026

Helsinn Healthcare S.A. sued Fresenius Kabi USA, LLC in the U.S. District Court for the District of Delaware after Fresenius filed an Abbreviated New Drug Application seeking approval for generic palonosetron hydrochloride injection, the active ingredient in Aloxi. The case, No. 1:15-cv-00918, involved Helsinn’s patents covering intravenous palonosetron dosage strengths, pharmaceutical compositions, and methods for preventing chemotherapy-induced nausea and vomiting.

The litigation formed part of a broader patent campaign against generic applicants, including Teva, Dr. Reddy’s Laboratories, Sandoz and Fresenius Kabi. The most important legal issue was whether Helsinn’s pre-critical-date commercial arrangements placed the claimed 0.25 mg palonosetron product “on sale” under 35 U.S.C. § 102. The Supreme Court later held in the related Helsinn v. Teva case that a confidential commercial sale can qualify as prior art under the America Invents Act.

What drug and regulatory filing triggered the Helsinn v. Fresenius litigation?

Fresenius challenged Helsinn’s U.S. market exclusivity for palonosetron hydrochloride injection, a 5-HT3 receptor antagonist used to prevent acute chemotherapy-induced nausea and vomiting.

Item	Detail
Brand	Aloxi
Active ingredient	Palonosetron hydrochloride
Dosage form	Intravenous injection
Relevant strength	0.25 mg/5 mL
Reference product sponsor	Helsinn Healthcare S.A., later commercialized in the U.S. through licensing and marketing arrangements
Regulatory pathway	ANDA
Defendant	Fresenius Kabi USA, LLC
Court	U.S. District Court for the District of Delaware
Case number	1:15-cv-00918
Complaint date	2015
Dispute type	Hatch-Waxman patent infringement litigation

Fresenius’s ANDA filing constituted a Paragraph IV certification against listed Helsinn patents. Helsinn responded by filing an infringement action under the Hatch-Waxman Act. The filing triggered the statutory 30-month stay on FDA approval of the ANDA, subject to later court orders, settlement terms, patent expiration and regulatory events.

What patents protected Aloxi and palonosetron injection?

The core patent family covered intravenous palonosetron formulations and the use of a 0.25 mg dose for preventing chemotherapy-induced nausea and vomiting.

Patent	General subject matter	Relevance to litigation
U.S. Patent No. 7,947,724	Palonosetron pharmaceutical compositions and dosage regimens	Core patent associated with the 0.25 mg intravenous product
U.S. Patent No. 8,598,219	Palonosetron formulations and therapeutic use	Continuation-family protection for intravenous palonosetron
U.S. Patent No. 8,729,094	Palonosetron treatment methods and dosage administration	Method-of-use protection
U.S. Patent No. 9,066,856	Later-issued palonosetron patent-family claims	Additional formulation or method coverage asserted in the generic litigation campaign

The specific patent claims at issue varied by defendant and procedural stage. The principal commercial dispute concerned claims covering the 0.25 mg intravenous dose of palonosetron used in Aloxi. The asserted claims did not depend solely on a broad claim to palonosetron as a chemical compound. Their value came from dosage, formulation and method-of-treatment limitations.

When did the relevant Aloxi patents lose exclusivity?

The expiration analysis depended on the individual patent, patent-term adjustment, patent-term extension and any terminal disclaimers. The principal commercial protection for the 0.25 mg intravenous palonosetron product extended into the early 2020s, with certain Orange Book-listed patents carrying expiration dates later than the earliest composition patents.

The critical distinction is between:

1. FDA regulatory exclusivity;
2. Orange Book patent protection;
3. patent-term adjustment;
4. patent-term extension; and
5. settlement-controlled generic launch rights.

Aloxi’s principal New Chemical Entity exclusivity expired before the Fresenius litigation. The case therefore centered on patent exclusivity rather than a remaining five-year NCE period.

Estimated exclusivity timeline

Event	Timing
Palonosetron development and original patent filings	Early 2000s
FDA approval of Aloxi injection	2003
Core patent-family issuance	2011 onward
Fresenius ANDA challenge	2015
Helsinn infringement action	2015
Related Federal Circuit litigation	2018 onward
Supreme Court decision on confidential sales	2019
Commercial generic-entry window	Controlled by patent expiration, litigation outcomes and settlements

The exact launch date for Fresenius depended on its settlement or final litigation position. A Hatch-Waxman case does not itself establish that the defendant may launch immediately after judgment. Launch may remain restricted by unexpired patents, court orders, settlement terms, regulatory approval or a separate licensing arrangement.

What was the central patent-law issue in Helsinn v. Fresenius?

The central issue was whether Helsinn’s commercial arrangements with MGI Pharma before the critical patent date invalidated the asserted claims under the on-sale bar.

Helsinn had entered into agreements involving the development, supply and commercialization of palonosetron. The agreements were not public in the sense that the dosage and pricing terms were fully disclosed. The related Supreme Court case addressed whether confidentiality prevented the transaction from qualifying as a sale under the America Invents Act.

The Supreme Court held that a sale or offer for sale may be prior art even when the transaction is confidential. The Court rejected the argument that the AIA changed the pre-existing rule by requiring public disclosure of the invention’s details. Helsinn Healthcare S.A. v. Teva Pharmaceuticals USA, Inc., 139 S. Ct. 628 (2019).

The ruling increased invalidity risk for Helsinn’s palonosetron patents. A commercial supply or license transaction can create an on-sale-bar issue even when:

• the transaction is confidential;
• the buyer does not receive unrestricted public disclosure;
• the agreement combines licensing and supply terms; and
• the product is not yet commercially marketed to patients.

How did the related Helsinn v. Teva decision affect the Fresenius case?

The Teva litigation created controlling guidance for the legal theory that applied across Helsinn’s generic cases. The Supreme Court’s decision resolved the statutory question but did not automatically dispose of every patent claim. The remaining analysis required determining whether the commercial agreement covered the invention claimed in each patent and whether the invention was ready for patenting before the critical date.

For the Fresenius case, the decision had three practical effects:

1. It weakened Helsinn’s position against invalidity arguments based on its earlier commercial arrangements.
2. It increased the leverage of generic defendants in settlement negotiations.
3. It created a material path to patent invalidity without requiring a finding that the generic product was noninfringing.

The legal impact was greatest for claims directed to the same 0.25 mg palonosetron formulation and dosing regimen reflected in Helsinn’s pre-critical-date agreements.

What were Fresenius Kabi’s likely Paragraph IV defenses?

Fresenius’s ANDA litigation position would have included the standard Hatch-Waxman defenses, subject to the patents and claims specifically asserted in the case.

Invalidity

The most significant invalidity theory was the on-sale bar under 35 U.S.C. § 102. Other potential defenses included:

• anticipation;
• obviousness under 35 U.S.C. § 103;
• lack of written description;
• lack of enablement;
• indefiniteness under 35 U.S.C. § 112; and
• lack of patentable distinction over earlier palonosetron disclosures.

The on-sale defense had unusual strength because the patent owner’s own commercial agreements supplied the factual basis for the challenge.

Noninfringement

Fresenius could argue that its proposed ANDA product did not satisfy one or more claim limitations. Relevant issues could include:

• concentration;
• dosage volume;
• excipient composition;
• pH;
• stability characteristics;
• administration instructions; and
• whether the proposed labeling induced infringement of a patented method.

ANDA infringement is assessed based on the product and labeling described in the application, not on all possible future commercial uses.

Method-of-use limitations

Method claims are more difficult to enforce when the generic label omits the patented use or presents a carve-out. If the label retained instructions for the patented chemotherapy-induced nausea and vomiting indication, Helsinn could pursue induced-infringement arguments under 35 U.S.C. § 271(e)(2) and § 271(b).

What was the Orange Book status of Aloxi?

The Orange Book listed Helsinn-related patents for palonosetron injection. Orange Book listings generally identify patents that the NDA holder represents as covering the approved drug, its formulation or an approved method of use.

An Orange Book listing can produce a statutory stay after a Paragraph IV notice. It does not establish that the listed patent is valid or infringed. A generic applicant can challenge the listed patent through:

• a Paragraph IV certification;
• a declaratory judgment action in limited circumstances;
• a district court infringement action brought by the NDA holder;
• an ANDA label carve-out; or
• settlement and licensed-entry arrangements.

For commercial analysis, Orange Book expiration dates should be treated as a screening tool. They do not replace review of terminal disclaimers, pediatric exclusivity, patent-term adjustment, patent-term extension and litigation settlements.

What was the litigation timeline for Case No. 1:15-cv-00918?

Date or period	Procedural development
2015	Helsinn filed suit in Delaware after Fresenius submitted an ANDA with Paragraph IV certifications
2015 onward	The parties litigated patent validity, infringement and claim-construction issues
2018	Federal Circuit decisions in related Helsinn litigation addressed patent validity and the on-sale bar
2019	Supreme Court held that a confidential sale can qualify as prior art under the AIA
After 2019	The Supreme Court ruling affected the litigation leverage and invalidity analysis in related Helsinn generic cases
Case disposition	The Fresenius matter was resolved through the federal Hatch-Waxman litigation process, including settlement and/or termination proceedings reflected in the docket

Public docket summaries should be read together with the underlying settlement order, stipulation of dismissal and any consent judgment. A docket termination alone does not disclose the commercial launch date unless the settlement terms were made public.

Did Fresenius obtain an authorized generic or licensed launch?

The public litigation record does not establish a broad, publicly disclosed license giving Fresenius an unrestricted launch date for all palonosetron products. In Hatch-Waxman settlements, launch rights may be structured through:

• a fixed date;
• an agreed date before patent expiration;
• a license limited to particular dosage forms;
• a supply arrangement;
• an authorized-generic agreement;
• a contingent launch following patent invalidity; or
• a covenant not to sue.

The absence of a publicly available business term sheet means the case should not be treated as evidence that Fresenius received a commercially material license unless the settlement documents expressly provide one.

Which companies challenged Helsinn’s palonosetron patents?

Helsinn faced a multi-defendant generic challenge involving several major ANDA filers.

Company	Role in the competitive patent landscape
Fresenius Kabi	ANDA filer and defendant in Case No. 1:15-cv-00918
Teva	Defendant in related litigation that produced the Supreme Court on-sale-bar decision
Dr. Reddy’s Laboratories	Generic palonosetron challenger
Sandoz	Generic pharmaceutical company involved in related patent disputes
Other ANDA applicants	Potential challengers depending on product strength, formulation and filing date

The presence of several challengers increased the probability of an eventual multi-source generic market. It also reduced the ability of any single defendant to preserve a long period of post-settlement exclusivity.

How strong was the Helsinn patent estate?

The estate was commercially meaningful but legally exposed.

Strengths

• The patents targeted the approved 0.25 mg intravenous regimen rather than merely a broad chemical entity.
• The patents were listed in the Orange Book.
• Method claims aligned with an FDA-approved use.
• Multiple continuation patents created overlapping claim categories.
• Helsinn could invoke the Hatch-Waxman 30-month stay against ANDA applicants.

Weaknesses

• The estate was vulnerable to the on-sale bar.
• The relevant commercial agreements originated with the patent owner and supplied documentary evidence.
• Closely related continuation patents could face similar prior-art arguments.
• Method-of-use claims depended on the generic label and actual promotional conduct.
• The core product had limited formulation complexity compared with a long-acting injectable, device, biologic or complex drug-delivery system.

Overall, Helsinn’s patent position was stronger against a conventional infringement theory than against a well-developed invalidity challenge based on the company’s own pre-critical-date transaction history.

What generic entry risks existed for Aloxi?

The primary risks were:

1. Patent invalidity risk. A successful on-sale-bar defense could eliminate protection before the nominal patent expiration date.
2. Multiple ANDA filers. Several generic companies could enter after the first permitted launch date.
3. Low formulation barriers. Palonosetron injection did not present the manufacturing complexity associated with biologics or extended-release delivery systems.
4. Method-label carve-outs. Generic applicants could limit labeling to avoid some patented uses.
5. Settlement-driven entry. A confidential or partly redacted settlement could permit entry before full patent expiration.
6. Price erosion. Injectable hospital products can experience rapid price pressure once more than one generic supplier enters.
7. Contracting concentration. Fresenius Kabi had established hospital and institutional distribution capabilities.

The most probable commercial outcome after multiple generic approvals was rapid price erosion rather than a single generic competitor retaining durable exclusivity.

How did palonosetron compare with competing antiemetic products?

Palonosetron competed with other 5-HT3 antagonists, including ondansetron and granisetron, as well as broader antiemetic regimens involving neurokinin-1 antagonists and corticosteroids.

Product	Active ingredient	Commercial distinction
Aloxi	Palonosetron	Longer duration and use in chemotherapy-induced nausea and vomiting
Zofran	Ondansetron	Earlier-generation 5-HT3 antagonist with extensive generic competition
Kytril	Granisetron	Competing 5-HT3 antagonist, also exposed to generic substitution
Akynzeo	Netupitant/palonosetron	Combination product with separate patent and regulatory considerations

Aloxi’s commercial defense depended on clinical positioning, contracting and formulary status after generic palonosetron entry. Patent protection alone was insufficient to preserve premium pricing once equivalent injectable products became available.

What was the revenue exposure from the Fresenius challenge?

The case threatened revenue from U.S. sales of intravenous Aloxi and related palonosetron products. The value at risk depended on:

• the timing of generic approval;
• the number of approved competitors;
• the settlement launch date;
• hospital contracting cycles;
• reimbursement policies;
• the availability of alternative antiemetics; and
• the extent to which Fresenius could supply institutional customers.

A single generic launch would likely produce moderate initial erosion. Two or more competing injectable suppliers would increase discounting and reduce the reference product’s negotiating leverage. Revenue exposure was therefore linked less to the nominal patent expiration date than to the first legally permitted generic entry date and the number of approved suppliers at launch.

What is the current legal significance of the case?

The case is important for three reasons.

First, it illustrates the risk of relying on confidential supply and commercialization agreements when patent claims are filed after those transactions. Second, it demonstrates how one Supreme Court decision can affect a group of parallel ANDA cases. Third, it shows that formulation and method-of-use patents can provide meaningful commercial protection but remain vulnerable when the patent owner’s own transaction history supports an on-sale-bar defense.

Key Takeaways

• Helsinn sued Fresenius Kabi in Delaware over an ANDA for generic intravenous palonosetron.
• The dispute involved the Aloxi patent family, including U.S. Patent Nos. 7,947,724, 8,598,219, 8,729,094 and 9,066,856.
• The key legal issue was whether Helsinn’s confidential pre-critical-date commercial arrangements triggered the on-sale bar.
• The Supreme Court later held that a confidential sale can qualify as prior art under the AIA.
• Orange Book listing created the Hatch-Waxman litigation mechanism but did not establish patent validity.
• Helsinn’s estate had meaningful dosage and method-of-use coverage but material invalidity exposure.
• Multiple generic challengers increased the probability of rapid price erosion after authorized entry.
• The Fresenius docket should be read with the settlement or dismissal documents to determine the precise launch rights and restrictions.

FAQs

Did Fresenius challenge Aloxi through a Paragraph IV certification?

Yes. The case was a Hatch-Waxman infringement action arising from Fresenius’s ANDA and Paragraph IV challenge to Helsinn-listed palonosetron patents.

Did the Supreme Court decide the Fresenius case directly?

No. The Supreme Court decided the related Helsinn Healthcare S.A. v. Teva Pharmaceuticals USA, Inc. case. Its interpretation of the on-sale bar affected the legal analysis in parallel Helsinn litigation, including the Fresenius dispute.

Were palonosetron method-of-use patents enforceable against generic labeling?

Potentially. Enforcement depended on whether the ANDA label instructed use for the patented indication and whether the generic applicant’s labeling or conduct supported induced infringement.

Does Orange Book listing guarantee that a palonosetron patent will block generic approval?

No. Listing can trigger the 30-month stay, but the patent may still be held invalid, not infringed or unenforceable.

Was Fresenius’s commercial launch date publicly established by the case number alone?

No. The launch date must be determined from the final judgment, settlement, dismissal order, FDA approval history and any publicly available agreement terms.

References

1. Helsinn Healthcare S.A. v. Fresenius Kabi USA, LLC, No. 1:15-cv-00918, U.S. District Court for the District of Delaware.

2. Helsinn Healthcare S.A. v. Teva Pharmaceuticals USA, Inc., 139 S. Ct. 628 (2019).

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

4. U.S. Patent and Trademark Office. (2024). Patent Center and patent term information for U.S. Patent Nos. 7,947,724, 8,598,219, 8,729,094 and 9,066,856. USPTO.

5. U.S. Code, 35 U.S.C. §§ 102, 103, 112, 271(e)(2).